Display options
Cite
Mari A, Antonelli A, Cindolo L, et al. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol. 2021;13:1756287221993283doi: 10.1177/1756287221993283.
Mari, A., Antonelli, A., Cindolo, L., Fusco, F., Minervini, A., & De Nunzio, C. (2021). Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Therapeutic advances in urology, 131756287221993283. https://doi.org/10.1177/1756287221993283
Mari, Andrea, et al. "Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis." Therapeutic advances in urology vol. 13 (2021): 1756287221993283. doi: https://doi.org/10.1177/1756287221993283
Mari A, Antonelli A, Cindolo L, Fusco F, Minervini A, De Nunzio C. Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis. Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021. PMID: 33912246; PMCID: PMC8047826.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021.

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.

Therapeutic advances in urology

Andrea Mari, Alessandro Antonelli, Luca Cindolo, Ferdinando Fusco, Andrea Minervini, Cosimo De Nunzio

Affiliations

  1. Department of Urology, University of Florence, Careggi Hospital, San Luca Nuovo, Florence, Italy.
  2. Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, University of Verona, Italy.
  3. Department of Urology, Villa Stuart Private Hospital, Rome, Italy.
  4. Department of Woman, Child and General and Specialized Surgery University of Campania "Luigi Vanvitelli", Naples, Italy.
  5. Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, Florence, Italy.
  6. Division of Urology, Ospedale Sant'Andrea, Sapienza University of Rome, Rome, Italy.

PMID: 33912246 PMCID: PMC8047826 DOI: 10.1177/1756287221993283

Abstract

BACKGROUND: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH.

METHODS: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website.

RESULTS: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin

CONCLUSIONS: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

© The Author(s), 2021.

Keywords: alfuzosin; alpha adrenoreceptor antagonists; benign prostatic hyperplasia; low urinary tract symptoms; pharmacology

Conflict of interest statement

Conflict of interest statement: Ferdinando Fusco: Speaker at symposiums and seminaries for Recordati, Astellas, Glaxo Smith Kline. Cosimo de Nunzio: Consultancy for Pierrefabre, Janssen, Sanofi, Glaxo

References

  1. Int J Impot Res. 2007 Sep-Oct;19(5):480-5 - PubMed
  2. BJU Int. 2000 Sep;86(4):432-8 - PubMed
  3. Circ Res. 1996 May;78(5):737-49 - PubMed
  4. Eur Urol. 2000 Feb;37(2):183-90 - PubMed
  5. Eur Urol. 2015 Jun;67(6):1099-1109 - PubMed
  6. J Sex Med. 2009 Feb;6(2):544-52 - PubMed
  7. BJU Int. 2005 Mar;95(4):603-8 - PubMed
  8. Urology. 2000 Nov 1;56(5 Suppl 1):20-2 - PubMed
  9. Ophthalmology. 2014 Apr;121(4):829-34 - PubMed
  10. Eur Urol. 2003 Dec;44(6):637-49 - PubMed
  11. BJU Int. 2003 Dec;92(9):1044; author reply 1044-5 - PubMed
  12. J Urol. 2014 Jan;191(1):130-7 - PubMed
  13. Br J Pharmacol. 1996 Nov;119(5):797-803 - PubMed
  14. Eur Urol. 2000 Mar;37(3):306-13 - PubMed
  15. Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8 - PubMed
  16. Br J Pharmacol. 1993 Aug;109(4):1282-9 - PubMed
  17. Trans Am Ophthalmol Soc. 2009 Dec;107:234-9 - PubMed
  18. Eur Urol. 2000 Jun;37(6):680-6 - PubMed
  19. BJU Int. 2005 May;95(7):1006-12 - PubMed
  20. PLoS Med. 2009 Jul 21;6(7):e1000100 - PubMed
  21. Eur Urol. 2002 Jan;41(1):54-60; discussion 60-1 - PubMed
  22. Int Neurourol J. 2015 Jun;19(2):107-12 - PubMed
  23. Korean J Urol. 2011 Apr;52(4):274-8 - PubMed
  24. Andrologia. 2012 May;44 Suppl 1:791-5 - PubMed
  25. Lancet. 1991 Jun 15;337(8755):1457-61 - PubMed
  26. Eur Urol. 2006 Dec;50(6):1292-6; discussion 1297-8 - PubMed
  27. BJU Int. 2006 Mar;97(3):513-9 - PubMed
  28. Br J Urol. 1997 Oct;80(4):597-605 - PubMed
  29. Eur Urol. 2007 Jun;51(6):1717-23 - PubMed
  30. Drugs. 2002;62(4):633-53 - PubMed
  31. Cent European J Urol. 2017 Jun 30;70(2):148-153 - PubMed
  32. Clin Interv Aging. 2015 Jan 17;10:277-86 - PubMed
  33. Urology. 2002 Feb;59(2):281-6 - PubMed
  34. Eur Urol. 2000 Apr;37(4):421-7 - PubMed
  35. Eur Urol. 2003 Jul;44(1):101-5 - PubMed
  36. BJU Int. 2006 Apr;97 Suppl 2:3-6; discussion 21-2 - PubMed
  37. J Urol. 2006 Jan;175(1):35-42 - PubMed
  38. BJU Int. 2008 Apr;101(7):847-52 - PubMed
  39. Int J Clin Pract. 2014 Apr;68(4):471-7 - PubMed
  40. Low Urin Tract Symptoms. 2014 Jan;6(1):35-40 - PubMed
  41. Asian J Urol. 2017 Jul;4(3):148-151 - PubMed
  42. Eur Urol. 1998 Sep;34(3):169-75 - PubMed
  43. Urology. 2000 Apr;55(4):540-6 - PubMed
  44. Aging Male. 2020 Dec;23(5):1432-1439 - PubMed
  45. BJU Int. 2004 Mar;93(4):605-8 - PubMed
  46. Drugs. 1993 Mar;45(3):410-29 - PubMed
  47. J Urol. 2006 Feb;175(2):624-8; discussion 628 - PubMed
  48. BJU Int. 2004 Apr;93(6):757-62 - PubMed
  49. Turk J Urol. 2015 Sep;41(3):125-31 - PubMed
  50. Eur Urol. 1997;31(2):190-8 - PubMed
  51. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35 - PubMed
  52. BJU Int. 2015 Apr;115(4):508-19 - PubMed
  53. Evid Based Med. 2016 Aug;21(4):125-7 - PubMed
  54. Gastroenterol Hepatol (N Y). 2012 Jun;8(6):376-83 - PubMed

Publication Types